

# Diagnosis and Management of Asthma in Adults

## A Review

Jennifer L. McCracken, MD; Sreenivas P. Veeranki, MBBS, DrPH; Bill T. Ameredes, MS, PhD; William J. Calhoun, MD

**IMPORTANCE** Asthma affects about 7.5% of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma.

**OBSERVATIONS** Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-acting  $\beta_2$ -agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-acting  $\beta_2$ -agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-acting  $\beta_2$ -agonists alone is not appropriate. Other controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab).

**CONCLUSIONS AND RELEVANCE** Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-acting  $\beta_2$ -agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.

JAMA. 2017;318(3):279-290. doi:10.1001/jama.2017.8372  
Corrected on October 24, 2017.

[+ Author Audio Interview](#)

[+ CME Quiz at jamanetwork.com/learning and CME Questions page 295](#)

**Author Affiliations:** Division of Allergy and Clinical Immunology, University of Texas Medical Branch, Galveston (McCracken, Calhoun); Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston (Veeranki); Division of Pulmonary Critical Care and Sleep, Department of Internal Medicine, University of Texas Medical Branch, Galveston (Ameredes, Calhoun).

**Corresponding Author:** William J. Calhoun, MD, University of Texas Medical Branch, 4.116 JSA, 301 University Blvd, Galveston, TX 77555-0568 (william.calhoun@utmb.edu).

**Section Editors:** Edward Livingston, MD, Deputy Editor, and Mary McGrae McDermott, MD, Senior Editor.

**A**sthma affects about 7.5% of adults in the United States, resulting in 1.8 million hospitalizations and 10.5 million physician office visits per year (Table 1). Asthma is more common in black (8.7%) and Puerto Rican Hispanic (13.3%) individuals than in white individuals (7.6%) and is associated with higher mortality in blacks than in whites (25.4 vs 8.8 per million annually) (Table 1). Inhaled corticosteroids increase the number of days without symptoms (by 7-21 d/mo), improve lung function (forced expiratory volume in first second of expiration [FEV<sub>1</sub>]) by 13% and peak flow by 23 to 41 L/min,<sup>7</sup> and reduce symptoms of dyspnea, cough, and nighttime awakening.<sup>8</sup>

Asthma exhibits considerable clinical and molecular heterogeneity (eg, atopic vs nonatopic, aspirin-exacerbated respiratory disease, obesity-associated asthma), which complicates diagnostic evaluations and affects therapeutic responsiveness.<sup>9</sup> For example, patients with asthma who smoke have relative resistance to inhaled corticosteroids.<sup>10</sup> Patients with asthma uncontrolled by standard treatment and with peripheral blood eosinophilia may benefit from mepolizumab or reslizumab, and those with elevated perennial allergen-specific IgE could be candidates for omalizumab.<sup>11</sup> Clinical history, spirometry, and assessment of allergic sensitivities are important for diagnosis of asthma.<sup>12,13</sup>

This review presents an evidence-based approach to the diagnosis and management of mild to moderate stable asthma in adults. For patients with severe disease, generally manifested as continuing symptoms and airway obstruction despite appropriate therapy,<sup>12,13</sup> consultation with an asthma specialist (allergist or pulmonologist) should be sought.

## Methods

The Cochrane Database of Systematic Reviews, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, MEDLINE, Population Information Online, PubMed, and Web of Science were searched for the period from the inception of each database through March 2017 for randomized clinical trials, systematic reviews, and/or meta-analyses and for observational studies using *asthma* or *anti-asthmatic drugs* or *asthma management or therapeutic* as primary search terms. Titles and abstracts of the articles were initially screened, and selected articles underwent full review. The bibliographies of selected articles were manually screened for additional relevant articles. All authors agreed on the final bibliography. Emphasis was given

**Table 1. Prevalence, Mortality, and Health Care Utilization Among Adults With Asthma in the United States**

Measure	Value
<b>Prevalence, %<sup>a</sup></b>	
Overall prevalence	7.4
<b>Sex</b>	
Male	5.1
Female	9.6
<b>Race/ethnicity</b>	
White non-Hispanic	7.6
Black non-Hispanic	8.7
Hispanic	5.8
Others	6.8
Hispanic of Puerto Rican origin	13.3
Hispanic of Mexican origin	4.9
<b>Asthma-Specific Mortality (Deaths per Million per Year)<sup>b</sup></b>	
Overall	14.1
<b>Race/ethnicity</b>	
White non-Hispanic	8.8
Black non-Hispanic	25.4
Hispanic	7.7
Others	9.9
<b>Health Care Utilization</b>	
<b>Inpatient discharges (rate per 10 000 per year)<sup>c</sup></b>	
Overall	13.0
<b>Race</b>	
White	8.7
Black	29.9
Other	12.6
Emergency department visits (in millions per year) <sup>d</sup>	1.8
Physician office visits (in millions per year) <sup>e</sup>	10.5
Hospital outpatient department visits (in millions per year) <sup>f</sup>	1.3

<sup>a</sup> Asthma prevalence by age, sex, and race/ethnicity as reported in 2014 National Health Interview Survey.

<sup>b</sup> Asthma mortality (deaths per million) as reported in 2014 National Centers for Health Statistics surveys. Death rates by age are age-adjusted to 2000 US Standard Population.

<sup>c</sup> Inpatient discharges as reported in the 2010 National Hospital Discharge Survey.

<sup>d</sup> Emergency department visits as reported in the 2013 National Ambulatory Medical Care Survey.

<sup>e</sup> Physician office visits as reported in the 2012 National Ambulatory Medical Care Survey.

<sup>f</sup> Hospital outpatient department visits as reported in the 2010 National Hospital Ambulatory Medical Care Survey.

to randomized clinical trials and articles that included information of interest to a general medical readership.

## Results

### Clinical Presentation

Asthma is a heterogeneous clinical syndrome affecting the lower respiratory tract. It presents as episodic or persistent symptoms of wheezing, dyspnea, air hunger, and cough. Symptoms may be precipitated or exacerbated by exposure to allergens and irritants, viral upper respiratory tract infections, bacterial

sinusitis, exercise, and cold air. Nocturnal symptoms indicate more severe disease, causing awakening in the early morning hours (for those with a normal diurnal schedule). The clinical presentation of asthma is variable with respect to severity, underlying pathogenic mechanisms, effect on quality of life, and responsiveness to treatment.<sup>9</sup>

Asthma may develop at any age, although onset is more frequent in childhood and young adulthood. Familial clustering occurs, suggesting that genetic factors are important.<sup>12-16</sup> Risk factors for asthma include heredity, exposure to environmental tobacco smoke, viral infections in the first 3 years of life, and socioeconomic factors such as income level, the presence of cockroach or rodent infestations in the home, and access to medical care.<sup>12</sup> Heritable factors include genes regulating IgE-related mechanisms,<sup>12,13</sup> glucocorticoid response,<sup>14</sup> airway smooth muscle development (*ADAM33*),<sup>15</sup> and components of the immune system (*HLA-G*).<sup>16</sup> Tobacco smoke is a common exacerbating factor in patients with asthma.<sup>13</sup>

Physical findings in stable asthma are nonspecific, and physical examination findings can be normal when the patient is well. Poorly controlled asthma may exhibit auscultatory wheezing or rhonchi, but the intensity of wheezing is a poor indicator of the severity of either airflow obstruction or disease pathology. In an acute exacerbation of asthma, tachypnea, pulsus paradoxus (eg, a decrease of more than 10 mm Hg in systolic blood pressure during inspiration), cyanosis, and use of accessory muscles of respiration may be evident.

The term "exacerbation" may be used to indicate a short-lived worsening of symptoms managed effectively with short-acting  $\beta_2$  agents. It also may be used to indicate a more serious deterioration of lung function, of longer duration, associated with increased symptoms and commonly precipitated by exposure to allergens or viral infections, that may require intensification of anti-inflammatory therapy.<sup>12,13</sup>

Atopic or allergic asthma is frequently associated with allergic rhinitis and conjunctivitis. Food allergies and atopic dermatitis may also be observed. Nonatopic asthma, defined as not associated with allergies, is less frequent than atopic asthma in patients with mild asthma (20%) or severe asthma (29%)<sup>17</sup> and is more common in older adults compared with children; its evaluation and pharmacologic management are otherwise similar to that for atopic disease.<sup>12,13</sup>

Adverse consequences of systemic steroid treatment may occur if frequent courses of systemic steroid therapy are necessary (Table 2). Allergic bronchopulmonary mycoses, including allergic bronchopulmonary aspergillosis, may have a prevalence as high as 25% among people with asthma,<sup>31</sup> although the pathogenesis and causes of this complication remain uncertain.<sup>12</sup>


In the setting of the above symptom complex and airway obstruction reversible by  $\beta_2$  agonists, the diagnosis of asthma can usually be made. A proposed algorithm for the diagnosis of asthma is presented in Figure 1. The combination of asthma-like symptoms and  $\beta_2$  agonist-reversible bronchial obstruction usually is sufficient to establish the diagnosis of asthma. Appropriate diagnostic testing should be conducted to confirm a diagnosis of asthma or suggest alternatives. Diseases of the heart and great vessels, the pulmonary parenchyma, and the upper airway can mimic the clinical presentation of asthma (Box).

**Table 2. Major Medical Therapies for Stable Asthma in Adults**

Category	Examples	Usual Dosing	Treatment Effect	Adverse Effects	Notes
<b>Standard Therapies</b>					
<b>Relievers</b>					
Short-acting $\beta_2$ -agonists (SABAs)	Albuterol Levalbuterol Pirbuterol	2 puffs every 4-6 h	Bronchodilation (7%-15% increase in FEV <sub>1</sub> , dose dependent)	Nervousness, tremor, bronchospasm, tachycardia, headache, pharyngitis	
Short-acting muscarinic antagonists (SAMAs)	Ipratropium	2-3 puffs every 6 h	Bronchodilation (7%-15% increase in FEV <sub>1</sub> , dose dependent)	Bronchitis, COPD exacerbation, dyspnea, headache	
<b>Controllers</b>					
Inhaled corticosteroids (ICSs)	Fluticasone	2 puffs twice daily	Decreased daytime and nocturnal symptoms	Upper respiratory tract infection, throat irritation, sinusitis, dysphonia, candidiasis, cough, bronchitis, headache	Comparisons for low, moderate, and high doses of ICSs are detailed elsewhere <sup>12,13</sup>
	Budesonide	2-4 puffs twice daily	Reduced exacerbations and death		
	Mometasone	Varies by device	Improved FEV <sub>1</sub> (improvement in symptoms, exacerbations, death, and FEV <sub>1</sub> are all dose dependent <sup>18,19</sup> )		
	Ciclesonide	160-320 $\mu$ g twice daily			
Leukotriene receptor antagonists (LTRAs)	Montelukast	10 mg daily	Decreased daytime and nocturnal symptoms	Headache, fatigue, abdominal pain, dyspepsia, mood changes	
	Zafirlukast	20 mg twice daily	Improved FEV <sub>1</sub> <sup>20</sup>		
Leukotriene synthesis inhibitor	Zileuton	600 mg 4 times daily	Improved FEV <sub>1</sub> <sup>21</sup>	Headache, pain, abdominal pain, dyspepsia, nausea, myalgia, increased alanine aminotransferase	Requires monitoring of hepatic enzymes  Drug interactions are common
Long-acting $\beta_2$ -agonists (LABAs)	Salmeterol	2 puffs twice daily	Improved FEV <sub>1</sub> <sup>22</sup>	Headache, rhinitis, bronchitis, influenza, dizziness	These agents should not be used without a simultaneous ICS agent
	Formoterol	2 puffs twice daily			
	Vilanterol	NA			
Long-acting muscarinic antagonist (LAMA)	Tiotropium	2 inhalations once daily	Improved FEV <sub>1</sub> <sup>23</sup>	Dry mouth, upper respiratory tract infection, pharyngitis, sinusitis, chest pain	
Combined ICSs/LABAs	Fluticasone/salmeterol inhaler	1 puff twice daily	Benefits of both ICSs and LABAs <sup>24</sup>	Nasopharyngitis, URI, headache, sinusitis, influenza, back pain	
	Fluticasone/salmeterol HFA	2 puffs twice daily			
	Budesonide/formoterol	2 puffs twice daily			
	Fluticasone/vilanterol	1 puff daily			
<b>Other Therapies</b>					
Oral corticosteroids	Prednisone	5-20 mg/d		Hypertension, increased appetite, weight gain, insomnia, mood changes, gastritis, skin atrophy, osteoporosis, adrenal suppression, avascular necrosis of bone	Doses listed are for chronic maintenance, not for exacerbations  Daily use of oral corticosteroids is not recommended unless other options are ineffective; consult with an asthma specialist
	Methylprednisolone	4-16 mg/d			
<b>Biologics</b>					
Anti-IgE	Omalizumab	Varies by weight	Reduced asthma exacerbations  Variable benefit in FEV <sub>1</sub> <sup>25</sup>	Injection site reaction, viral infections, URI, sinusitis, headache, pharyngitis, anaphylaxis	Used primarily by asthma specialists
Anti-IL-5	Mepolizumab	100 mg subcutaneously monthly	Reduced asthma exacerbations	Headache, injection site reaction, back pain, fatigue, oropharyngeal pain	Used primarily by asthma specialists
	Reslizumab	Varies by weight, IV administration	Small improvement in FEV <sub>1</sub> <sup>26-29</sup>		
Bronchial thermoplasty		3 Bronchoscopic treatments, once monthly for 3 mo	Reduced asthma exacerbations, emergency department visits through at least 1 y <sup>30</sup>	Short-term worsening of asthma symptoms, cough, wheezing, chest pain, URI, infection	Specialty treatment  Durability of benefit is controversial

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in first second of expiration; URI, upper respiratory infection.

Figure 1. Proposed Algorithm for Initial Diagnosis of Asthma



The first diagnostic test should be forced expiratory spirometry, categorized as obstructed (ratio of forced expiratory volume in first second of expiration [FEV<sub>1</sub>] to forced vital capacity [FVC] less than lower limit of normal) or not obstructed. If airway obstruction is present, a bronchodilator response following 2 to 4 puffs of short-acting β<sub>2</sub>-agonist should be determined. Fixed or partially reversible airway obstruction suggests alternative diagnoses, although severe asthma may be present. PC<sub>20</sub> indicates the methacholine concentration required to achieve a 20% decrease in FEV<sub>1</sub>.

**Box. Differential Diagnosis of Asthma**

- Upper respiratory tract
  - Vocal cord dysfunction
  - Congestive rhinopathy
  - Obstructive sleep apnea syndrome
- Lower respiratory tract
  - Chronic obstructive pulmonary disease
  - Occupational bronchitis
  - Cystic fibrosis
  - Bronchiectasis
  - Pneumonia
- Gastrointestinal tract
  - Gastroesophageal reflux disease
- Cardiovascular system
  - Congestive heart failure
  - Pulmonary hypertension
  - Chronic thromboembolic pulmonary disease
- Central nervous system
  - Habitual cough

**Pathophysiology**

**Variable Airway Obstruction**

A cardinal feature of asthma is variable airway obstruction,<sup>32</sup> a variation in airway caliber over the time frame of minutes to days; it is due to bronchoconstriction, mucosal inflammation, and luminal secretions, and results in increased airflow resistance and work of breathing. In more severe or longstanding disease, the airway obstruction may be entirely fixed or incompletely reversible with bronchodilator treatment.<sup>17</sup> Bronchoconstriction occurs in airways that contain contractile airway smooth muscle. Enhanced parasympathetic cholinergic tone occurs in nocturnal asthma and can cause contraction of airway smooth muscle, increased mucus production, and in-

creased airway obstruction.<sup>33</sup> Factors associated with mucus overproduction and inflammation (allergen exposures, viral or bacterial infections)<sup>34</sup> can also increase obstruction.

**Airway Hyperresponsiveness**

Airway hyperresponsiveness,<sup>32</sup> an exaggerated reduction in airway caliber after a stimulus, has been recognized as a hallmark of asthma from the time of Claudius Galen, a physician in about AD 150.<sup>35</sup> Although not specific, airway hyperresponsiveness is a virtually universal finding in asthma, and is associated with airway inflammation. Airway hyperresponsiveness may be induced by allergens (eg, pollen, animal danders),<sup>36</sup> chlorine,<sup>37</sup> pollutants (eg, sulfur dioxide),<sup>38</sup> diesel exhaust particulates,<sup>36</sup> and viral upper respiratory tract infections.<sup>39</sup> Genetic variation accounts for some associations of environmental exposure and airway hyperresponsiveness,<sup>40</sup> but specific genetic predispositions for airway hyperresponsiveness and other triggers remain poorly understood. Sympathetic control in the airway is mediated via β<sub>2</sub>-adrenoreceptors expressed on airway smooth muscle,<sup>41</sup> which are responsible for the bronchodilator response to albuterol used in diagnosis and symptom relief and for longer-term bronchodilation facilitated by long-acting β<sub>2</sub>-agonist controller agents.<sup>42</sup> (Short- and long-acting β<sub>2</sub>-agonists are used for distinct purposes in asthma therapy.) Cholinergic pathways may further contribute to airway hyperresponsiveness<sup>43</sup> and are the basis for the efficacy of anticholinergic therapy.<sup>23,44</sup> The methacholine challenge test uses inhaled methacholine, a direct cholinergic agonist, to evoke concentration-dependent airway smooth muscle contraction.<sup>45</sup> Bronchoconstriction at low concentrations of methacholine (typically <4 mg/mL) suggest increased airway hyperresponsiveness (Figure 1).

**Airway Inflammation**

Airway inflammation is recognized as a pathogenic factor in asthma.<sup>46</sup> Inflammation involves many different cells (eosinophils,

Figure 2. National Asthma Education and Prevention Program Approach to Classification of Asthma Severity

Components of severity		Classification of asthma severity (age ≥12 y)			
		Intermittent	Persistent		
			Mild	Moderate	Severe
Impairment	Symptoms	≤2 d/wk	>2 d/wk but not daily	Daily	Throughout the day
	Nighttime awakenings	≤2× mo	3-4× mo	>1× wk but not nightly	Often 7× wk
	Short-acting β <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤2 d/wk	>2 d/wk but not daily, and not more than 1× on any day	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
	Lung function Normal FEV <sub>1</sub> : FVC ratio 20-39 y 80% 40-59 y 75% 60-80 y 70%	<ul style="list-style-type: none"> <li>• Normal FEV<sub>1</sub>, between exacerbations</li> <li>• FEV<sub>1</sub>, &gt;80% predicted</li> <li>• FEV<sub>1</sub>: FVC normal</li> </ul>	<ul style="list-style-type: none"> <li>• FEV<sub>1</sub>, &gt;80% predicted</li> <li>• FEV<sub>1</sub>:FVC normal</li> </ul>	<ul style="list-style-type: none"> <li>• FEV<sub>1</sub>, &gt;60% but &lt;80% predicted</li> <li>• FEV<sub>1</sub>:FVC normal</li> </ul>	<ul style="list-style-type: none"> <li>• FEV<sub>1</sub>, &lt;60% predicted</li> <li>• FEV<sub>1</sub>:FVC reduced &gt;5%</li> </ul>
Risk	Exacerbations requiring oral systemic corticosteroids	0-1/y	≥2/y	≥2/y	≥2/y
		Consider severity and interval since last exacerbation Frequency and severity may fluctuate over time for patients in any severity category Relative annual risk of exacerbation may be related to FEV <sub>1</sub>			
Recommended step for initiating treatment (see Figure 3 for treatment steps)		Step 1	Step 2	Step 3 and consider short course of oral systemic corticosteroids	Step 4 or 5
In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly					

An estimate of asthma severity on initial presentation is made on the basis of daytime and nocturnal symptoms, the frequency of need for short-acting β<sub>2</sub>-agonists for relief of symptoms, the degree to which asthma interferes with normal activity, the degree of airway obstruction measured by spirometry, and the history of asthma exacerbations. On the basis of these factors, asthma can be categorized as intermittent, or persistent (mild, moderate, or severe).

This categorization informs the initial therapeutic approach (Figure 3). EIB indicates exercise-induced bronchoconstriction; FEV<sub>1</sub>, forced expiratory volume in first second of expiration; FVC, forced vital capacity.

Figure adapted from NAEPP.<sup>12</sup>

lymphocytes, mast cells, neutrophils) and is commonly initiated by allergen-dependent release of histamine and other mediators from mast cells<sup>47</sup> and subsequent infiltration of lymphocytes (particularly T-helper type 2 [T<sub>H</sub>2]) and granulocytes into the airway.<sup>48</sup> IgE occupies a central role in the pathogenesis of allergic asthma; inflammatory responses are mediated by allergen-specific IgE, generated during allergic sensitization, and bound to mast cells which are activated by reexposure to allergen. Elevated levels of proinflammatory cytokines IL-4, IL-5, and IL-13 are observed.<sup>49,50</sup> Airway inflammation accentuates obstruction by promoting mucosal infiltration and edema, mucus secretion, and airway hyperresponsiveness; it also predisposes to exacerbations. Structural changes, termed airway remodeling, include increased smooth muscle mass,<sup>51</sup> goblet cell hyperplasia,<sup>52</sup> and lamina reticularis thickening.<sup>51</sup> The T<sub>H</sub>2 hypothesis (activation of T<sub>H</sub>2 cells) provides conceptual understanding of the development of inflammation associated with asthma.<sup>53</sup> More recently it has been recognized that type 2 innate lymphoid cells also contribute to eosinophilic airway inflammation. This phenomenon is termed “type 2 inflammation.”<sup>54</sup> Eosinophilic inflammation and asthma may develop in the absence of overt allergy.<sup>55</sup> Endogenous anti-inflammatory mediators appear to be important in controlling and resolving airway inflammation in individuals without asthma, and these mechanisms may be insufficiently or ineffectively activated in asthma: eg, reduced production of the anti-inflammatory factors IL-10 and lipoxin A4 has been identified in patients with asthma.<sup>56,57</sup>

Activation of IL-17, CD4<sup>+</sup> T cells (T<sub>H</sub>17 cells), and IL-12/IL-23 is distinct from type 2 factors noted above and is more closely associated with neutrophilic inflammation.<sup>58</sup> Neutrophil infiltration and activation contribute to the severity of uncontrolled and severe asthma, and neutrophilic inflammation is less responsive to standard therapies, making the neutrophil an attractive potential target for novel asthma therapy.<sup>59</sup>

**Assessment and Diagnosis**

The diagnosis and severity of asthma are established based on clinical criteria: history, physical examination, and evidence of either reversible airflow obstruction, or airway hyperresponsiveness (Figure 1).<sup>12,13</sup> The US National Asthma Education and Prevention Program (NAEPP) approach to classifying asthma severity is based on 2 domains: impairment and risk. The impairment domain includes measured airway obstruction, the frequency and intensity of daytime and nocturnal symptoms, frequency of short-acting β<sub>2</sub> agonist use for symptom relief, and interference of daily activities by symptoms. The risk domain assesses the frequency of exacerbations (Figure 2). These data collectively define both asthma severity and asthma control.<sup>12,13</sup> Physical findings of accessory muscle use or audible wheezing during normal breathing may be present only during times of asthma exacerbation and have poor negative predictive value to exclude the diagnosis of asthma.

Spirometry is the most important diagnostic procedure for evaluating airway obstruction and its reversibility. It should

Table 3. Diagnostic Modalities Useful in Diagnosis and Treatment of Stable Asthma in Adults

Diagnostic Modality	Suggests Asthma	Other Differential Features
Clinical history	Wheezing, coughing, chest tightness May only be present or worsened with exertion, upper respiratory infection, seasonal or perennial allergies Nocturnal cough, particularly 2 AM to 4 AM Need for short-acting $\beta_2$ -agonist inhaler for relief of symptoms Personal or family history of atopy	Occupational exposures Dyspnea only on exertion may suggest COPD Family history is often positive in atopic asthma Seasonal variation of symptoms or asthma severity is consistent with atopic asthma
Spirometry	Airway obstruction evidenced by FEV <sub>1</sub> :FVC ratio <lower limit of normal Demonstrated reversibility of obstruction by increase in FEV <sub>1</sub> $\geq$ 200 mL and $\geq$ 12% from baseline measure after inhalation of 2-4 puffs of short-acting $\beta_2$ -agonist Normal spirometry findings are not inconsistent with asthma	Airflow limitation that is irreversible or partially reversible may suggest COPD, bronchiectasis, or other obstructive disease
Bronchoprovocation with methacholine	20% or more decrease in FEV <sub>1</sub> with after inhalation of low concentration (<4 mg/mL) of methacholine; used principally in patients with symptoms consistent with asthma but who exhibit normal pulmonary function tests	Specificity and positive predictive value are low Allergic rhinitis, congestive heart failure, chronic bronchitis may all exhibit increased methacholine response
Impedance oscillometry	Elevated airway resistance at 5 Hz, elevated area of reactance, increased resonant frequency (Fres), reactance at 5Hz more negative than predicted	Increased total airway resistance at 5 Hz in comparison with large-airway resistance at 20 Hz suggests small-airway disease
Chest radiograph or CT scan of thorax	Usually normal but can exclude other diagnoses such as emphysema, lung cancer, infiltrative diseases, pneumonia	Central bronchiectasis may suggest allergic bronchopulmonary aspergillosis
CBC	Eosinophilia, particularly >300/ $\mu$ L; results can inform selection for mepolizumab or reslizumab therapy	Eosinophil count <150 mitigates against use of anti-IL-5 therapies
Serum total IgE	Elevated in atopic asthma, not in nonatopic asthma; can inform selection of omalizumab therapy	IgE >1000 IU/mL: consider allergic bronchopulmonary aspergillosis, atopic dermatitis, and other allergic manifestations
Skin prick testing or serum-specific IgE for aeroallergens	Positive, particularly for perennial allergens, or seasonal allergens with corresponding seasonal variation in asthma symptoms; may be negative in nonatopic asthma; can inform omalizumab therapy Positive testing can guide allergen avoidance strategies <sup>12</sup>	Positive test for <i>Aspergillus fumigatus</i> or <i>A niger</i> suggests possibility of allergic bronchopulmonary aspergillosis
Fractional excretion of nitric oxide	Intermediate level: 25-50 ppb in patients aged $\geq$ 12 y High level: >50 ppb in patients aged $\geq$ 12 y	Low levels are not inconsistent with asthma Levels >20 may identify omalizumab-responsive patients

Abbreviations: CDC, complete blood cell count; COPD, chronic obstructive pulmonary disease; CT, computed tomography; FEV<sub>1</sub>, forced expiratory volume in first second of expiration; FVC, forced vital capacity.

be performed in all patients in whom asthma is a diagnostic consideration. The maximal volume of air forcibly exhaled from the point of maximal inhalation (forced vital capacity, FVC), the volume of air exhaled during the first second of this maneuver (FEV<sub>1</sub>), and FEV<sub>1</sub>:FVC ratio are 3 key measures. An FEV<sub>1</sub>:FVC ratio less than the lower limit of normal (0.7-0.8 in adults, depending on age) (Figure 2) indicates airway obstruction, although asthma may be present even without demonstrable airway obstruction (Figure 1). Reversibility of airway obstruction is indicated by an increase in FEV<sub>1</sub> of 200 mL or greater and 12% or greater from baseline after inhalation of short-acting  $\beta_2$ -agonists. In patients who have smoked cigarettes, distinguishing asthma with partially reversible obstruction from chronic obstructive pulmonary disease is challenging and has led to the description of an asthma-chronic obstructive pulmonary disease overlap syndrome, the existence and clinical importance of which is controversial.<sup>60</sup> No validated approaches for differentiating these entities has been identified. A low diffusing capacity for carbon monoxide suggests an element of emphysema rather than asthma. Pulmonary function testing is less informative when performed during exacerbations of asthma and is best obtained during times of disease stability.


Bronchoprovocation with methacholine can be helpful in patients with suspected asthma and normal spirometry because a negative test result makes the diagnosis of asthma unlikely (Figure 1).<sup>61</sup> Outside the United States, mannitol may be used as an effective bronchoprovocation agent.<sup>62</sup> Methacholine and mannitol used as bronchoprovocation agents both have a sensitivity of approximately 80% and specificity of approximately 65%.<sup>63</sup>

Impedance oscillometry, a technique that measures airway resistance without forced expiration, can measure central and peripheral airway resistance in those patients for whom the forced expiratory maneuver is difficult or impossible, including elderly patients.<sup>64</sup> However, there is no consensus on the incremental value of impedance oscillometry over spirometry alone, nor are there sufficient data to establish the performance characteristics (sensitivity, specificity) of oscillometry vs spirometry alone in asthma.

In stable asthma, measurement of arterial blood gas values is rarely necessary, although it may be helpful in cases of acute decompensation and exacerbation. Periodic monitoring of pulse oximetry, with or without exercise, may be useful. Allergy evaluation has become increasingly important in recent years, as biologic agents have become available for treatment. A total serum IgE and specific IgE for common aeroallergens may be performed,<sup>12,13</sup> as these tests can guide allergen avoidance strategies and suggest the potential use of anti-IgE monoclonal therapeutics. Allergy skin testing may be substituted for serum measures of allergen-specific IgE.<sup>12</sup> A complete blood cell count with an elevated absolute eosinophil count can identify appropriate candidates for anti-IL-5 therapies (mepolizumab  $\geq$ 150/ $\mu$ L and reslizumab  $\geq$ 400/ $\mu$ L).

These diagnostic modalities are summarized in Table 3. The NAEP<sup>12</sup> presents a severity classification system based on historical features and spirometric measurements, and recently updated Global Initiative for Asthma (GINA) guidelines are also now available.<sup>13</sup> Severity classes of intermittent, mild persistent, moderate persistent, and severe persistent asthma are defined, and severity categorization determines initial therapeutic approaches (Figure 3). The GINA guidelines also outline assessment of severity in patients already receiving effective controller therapy.<sup>13</sup>

Figure 3. National Asthma Education and Prevention Program Recommendations for Asthma Therapy



All patients with asthma should have a rescue inhaler composed of a short-acting  $\beta_2$ -agonist (eg, albuterol). Preferred initial therapy is outlined by step. Periodic reevaluation of asthma symptoms, lung function, and exacerbations is necessary to guide adjustments in treatment. Alphabetical order is used when more than 1 treatment option is listed within either

preferred or alternative therapy. EIB indicates exercise-induced bronchoconstriction; ICS, inhaled corticosteroid; LABA, long-acting  $\beta_2$ -agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting  $\beta_2$ -agonist.  
Figure adapted from NAEPP.<sup>12</sup>

Asthma symptom control, using validated patient questionnaires (Asthma Control Test [ACT], Asthma Quality of Life Questionnaire [AQLQ], or Asthma Control Questionnaire [ACQ]) to provide a quantitative assessment of symptoms, may be assessed at each visit.<sup>12,65,66</sup> (Because asthma symptoms and pulmonary function may not correlate well, measurement of both can inform adjustments to therapy.) Spirometry should be repeated every 1 to 2 years or with clinically significant change of asthma control to identify accelerated loss of lung function.<sup>12</sup> Home peak flow monitoring may be useful in some patients for whom routine office spirometry cannot be performed. Patients with relatively normal pulmonary function test results, but persistent symptoms (eg, abnormal ACT, ACQ, or AQLQ scores) may be candidates for intensification of treatment. Persistently abnormal findings from pulmonary function tests suggest the need for intensification of the controller regimen. The utility of routine monitoring of the concentration of exhaled nitric oxide has not been established; however, patients who are not receiving adequate doses of inhaled steroids may show elevated concentrations (ie, >50 ppb) of exhaled nitric oxide.<sup>67</sup>

There is little evidence to demonstrate the value of routine chest radiography in asthma. Chest imaging, beginning with a standard 2-view chest radiograph, may help to exclude other pulmonary pathology.<sup>12</sup> Patients who are older than 65 years, have a clinically important history of smoking or significant occupational exposures such as mineral or organic dusts, have persistent symptoms

despite therapy, or present with long-standing disease may be at risk for chronic obstructive pulmonary disease or lung cancer.<sup>12,13</sup> The optimal imaging modality has not been established; low-dose, high-resolution computed tomographic scanning provides considerably more information than a standard chest radiograph, but with increased radiation exposure and higher cost.

**Treatment**

The goals of asthma treatment are reducing impairment (reducing symptoms, maintaining normal activities, achieving [nearly] normal pulmonary function test values) and minimizing risks associated with the disease (future exacerbations, medication adverse effects). Because of the heterogeneous nature of asthma and the limited availability of predictive biomarkers for treatment success, clinicians must approach patients with a guideline-based plan that recognizes specific environmental triggers and their mitigation (eg, allergens, viruses, or irritants encountered in occupational, household, or environmental settings), individual variability in the dose and particle size of inhaled corticosteroids, the class of long-acting bronchodilator (long-acting  $\beta_2$  agonist vs long-acting muscarinic antagonist), and other individual factors to provide an individualized treatment plan. A written asthma action plan that details in lay language the signs and symptoms indicating worsening of asthma, such as increased dyspnea or cough, or need for more frequent use of the  $\beta_2$  agonist inhaler, and the steps required to mitigate that worsening, is a key component of management.

Pharmacologic options are classified as either reliever (short-term benefit) or controller (longer-term benefit) medications (Table 2). All patients with asthma should have access to a short-acting  $\beta_2$  agonist inhaler (commonly albuterol) for treatment of acute symptoms; this intervention alone is appropriate for patients with intermittent asthma, defined as symptoms less than twice weekly with (near) normal pulmonary function. For patients with persistent asthma (defined as symptoms more than twice weekly or abnormal pulmonary function), a daily maintenance controller is generally appropriate. The initial choice of medication is directed by severity of asthma classification (intermittent; mild, moderate, or severe persistent [Figure 2]) at diagnosis. In the United States, guidelines recommend treatment based on 6 steps (Figure 3),<sup>12</sup> but the GINA guidelines define 5 steps, which are not strictly comparable to the US guidelines.<sup>13</sup>

In the US treatment guidelines, step 1 therapy is used for patients with intermittent asthma and consists of short-acting  $\beta_2$  agonists, administered as needed. (These agents are also used for quick symptom relief in all patients with asthma, irrespective of severity.) Step 2 therapy is indicated for mild persistent asthma and preferably consists of low-dose inhaled corticosteroids, which improve asthma outcomes such as lung function, symptoms, and exacerbations<sup>7,8,12,13</sup> in a dose-dependent, but not necessarily dose-proportionate, manner (eg, a doubled dose of inhaled corticosteroids will not produce doubled improvement in lung function). The dose response to inhaled corticosteroids varies by the outcome measured (symptom reduction, lung function improvement, reduction in exacerbation).<sup>12</sup> Inhaled corticosteroids reduce the infiltration and activation of eosinophils,  $T_H2$  cells, and other inflammatory cells. An oral leukotriene receptor antagonist may be as effective as inhaled corticosteroids and is an alternate first-line treatment.<sup>68</sup> These agents block the action of cysteinyl leukotrienes, key mediators of airway smooth muscle contraction.

Patients with moderate persistent asthma should start at step 3 therapy with medium-dose inhaled corticosteroids or a combination of low-dose inhaled corticosteroids and a long-acting  $\beta_2$  agonist (Table 2). Longer-acting bronchodilators increase airway caliber for 12 to 24 hours. Spacers (large volume-holding chambers) may improve pulmonary delivery, reduce pharyngeal delivery, and reduce local adverse effects when used with compatible pressurized metered-dose inhaler systems, particularly for those patients for whom consistent coordination of inhalation with actuation of the device is a concern.

Patients diagnosed with severe persistent asthma, commonly characterized as near-continuous chest symptoms, the need for multiple inhalations daily of rescue  $\beta_2$  agonist, nightly awakenings from asthma symptoms, or FEV<sub>1</sub> less than 60% predicted, should start at step 4, 5, or 6 and be referred for consultation with an asthma specialist (an allergist or pulmonologist).<sup>12,13</sup> Medication options for these patients include medium- or high-dose inhaled corticosteroid plus long-acting  $\beta_2$  agonist combinations, inhaled long-acting muscarinic agonists (tiotropium),<sup>23</sup> and biologic therapy.<sup>11-13</sup>

Long-acting bronchodilators should never be prescribed without an accompanying inhaled corticosteroid. The US Food and Drug Administration–approved package insert of each long-acting  $\beta_2$  agonist contains a black box warning of the increased


risk of adverse outcomes and death. However, recent prospective evidence suggests that long-acting  $\beta_2$ -agonists, when used appropriately (ie, always in combination with inhaled corticosteroids), do not confer adverse safety consequences and in fact reduce the risk of exacerbations and adverse events in adults with moderate to severe asthma compared with inhaled corticosteroids alone.<sup>69</sup>

For suboptimally controlled asthma, a physician should search for common problems such as incorrect inhaler technique, poor adherence, exposure to allergens, exposure to personal or second-hand tobacco smoke, gastroesophageal reflux, sinusitis, or intercurrent viral infections. If control is not optimal, intensification of the therapeutic regimen is usually indicated. The precise timing of follow-up visits is a matter of clinical judgment, as no prospective trials exist that directly address this question. Follow-up may range from several days or weeks for patients with very poorly controlled or severe disease, to months for patients with well-controlled, milder, and stable asthma. Once asthma is well controlled for 2 to 3 months, treatment may be stepped down to the lowest dose of medication that adequately controls symptoms and lung function.<sup>12,13</sup> Guidelines for deintensification of asthma therapy are not as well established as those for intensification, and there are no randomized clinical trials of step-down therapy on which to make specific recommendations.

For patients who continue to have uncontrolled asthma despite standard inhaled therapies, several parenteral biologic agents (monoclonal antibodies) are available. These agents act systemically by influencing the immunopathogenesis of asthma, rather than treating the consequences of inflammation and bronchospasm from within the airway, as standard controller therapies do (Figure 4). The central role of IgE in the pathogenesis of allergic airway disease makes IgE an attractive target for asthma therapy. Omalizumab is an anti-IgE monoclonal antibody used in allergic asthma accompanied by moderately elevated IgE level (30 to about 1000 IU/mL, depending on body weight) and evidence of sensitization to perennial aeroallergens. It reduces allergen-induced mast cell activation and decreases expression of IgE high-affinity receptors on mast cells<sup>70</sup> (Figure 4). Omalizumab is given by subcutaneous injection every 2 to 4 weeks, at a dose and frequency determined by body weight and serum IgE levels, and is principally effective in reducing exacerbations and need for oral steroids.<sup>70</sup> Retrospective analysis of omalizumab trials suggests that serum eosinophil counts in excess of 260/ $\mu$ L and fractional excretion of nitric oxide of at least 19.5 ppb may identify patients likely to improve with omalizumab. However, no biomarker has been subjected to rigorous prospective confirmation to determine its predictive value.<sup>70</sup> Little improvement in pulmonary function is observed, so lung function testing is not a good monitoring tool to assess omalizumab response. Measurement of serum IgE levels after initiating treatment is not useful. The primary clinical outcomes by which response may be judged are asthma exacerbations and symptoms.

Interleukin 5 is centrally involved in the synthesis, maturation, homing, and activation of eosinophils, suggesting a role for anti-IL-5 in managing eosinophilic airway disease. Anti-IL-5 monoclonal antibodies (mepolizumab and reslizumab) have recently been approved in the United States for patients with severe asthma and peripheral eosinophilia.<sup>11</sup> Mepolizumab reduces the rate of exacer-

Figure 4. Contrasting Standard vs Biologic Therapies in Asthma



Standard asthma therapy is commonly delivered via the airway, by therapeutic aerosols of inhaled corticosteroids (ICSs) or bronchodilators, and by design have effects largely limited to the environment of the airway. The cysteinyl leukotriene receptor (type 1) antagonist montelukast (and others) is delivered to the airway by the systemic circulation and reduces smooth muscle contraction and inflammation, particularly that due to activated eosinophils. Biologic therapy in asthma acts upstream of the inflammatory process in the airway.<sup>11</sup> Omalizumab reduces mast cell activation and release of mediators of bronchoconstriction (principally histamine and cysteinyl leukotrienes) and reduces production of proinflammatory cytokines, including IL-5. IL-5 is produced by several types of cells, including T<sub>H</sub>2 lymphocytes and type 2 innate

lymphoid cells (ILC2), and by activated mast cells. IL-5 has protean effects on eosinophil poesis, maturation in the bone marrow, emigration into the circulation, migration to sites of inflammation, and activation to produce oxidative damage and toxic eosinophil granule protein release. Mepolizumab and reslizumab reduce the activity of IL-5 at all these sites and reduce eosinophilic inflammatory responses. Individually and collectively, airway inflammation, airway hyperresponsiveness, and bronchoconstriction may produce structural airway changes of increased smooth muscle mass, thickened lamina reticularis, and mucus gland hypertrophy, collectively known as airway wall remodeling. It has not been proven that any asthma therapy reduces or eliminates airway wall remodeling.

bations by almost 50%; the need for oral corticosteroids is also reduced by 50%, with little effect on lung function.<sup>26,27</sup> No specific level of peripheral blood eosinophilia is listed in the package insert, but the referenced clinical trials required at least 150 eosinophils/ $\mu$ L. This level of eosinophilia has not been prospectively assessed as a predictive biomarker of therapeutic response. Mepolizumab is administered by injection every 4 weeks, at a standard dose of 100 mg subcutaneously.

Reslizumab is administered every 4 weeks by intravenous infusion, using weight-based dosing (3 mg/kg). Reslizumab reduces the rate of exacerbations by about 50%, reduces symptoms, and improves FEV<sub>1</sub> by 110 mL.<sup>28,29</sup> Clinical trials referenced in the package insert required at least 400 eosinophils/ $\mu$ L for entry, but this requirement has not been validated as a predictive biomarker. Both mepolizumab and reslizumab reduce biologic activity of IL-5 in the pathogenesis of eosinophilic inflammation (Figure 4).

Oral steroids are an effective option for uncontrolled disease and for asthma exacerbations but have significant adverse effects, including glucose intolerance, weight gain, and salt and water retention, if used continuously (Table 2).

### Special Considerations

Consultation with an asthma specialist is warranted for patients who are at step 4 or higher in the US guideline<sup>13</sup> or who have a life-threatening exacerbation, poor responsiveness to prescribed treatment, occupational triggers, atypical presentation, need for more than 2 bursts of oral corticosteroids, or who need specialized testing for allergies, lung function, or bronchoscopy.<sup>12,13</sup> Asthma may present with symptoms predominantly in association with exercise. The timing of symptoms is generally within a few minutes of cessation of exercise and is termed "exercise induced bronchospasm." Pre-treatment with albuterol 15 minutes prior to anticipated exercise can minimize or eliminate these symptoms.<sup>12,13</sup> Management of comorbid conditions (allergic rhinitis, sinusitis, gastroesophageal reflux, obstructive sleep apnea) improves asthma control.<sup>12,13</sup> Adding exercise as a component of lifestyle change in overweight patients with asthma appears to improve asthma control.<sup>71</sup>

### Selected Current Controversies

All long-acting  $\beta_2$ -agonists marketed in the United States carry a black box warning for increased risk of death and serious adverse

events, based primarily on results from a large observational study with important limitations in study design.<sup>72</sup> More recent evidence suggests that the appropriate use of long-acting  $\beta_2$ -agonists in combination with inhaled steroids is not associated with increased serious adverse events.<sup>69</sup> Additional well-controlled studies may clarify this matter.

All biologic agents marketed in the United States require parenteral administration and are costly (\$15 000-\$30 000 annually). Omalizumab and reslizumab carry black box warnings for the risk of anaphylaxis, and their use is generally limited to asthma specialists. No data are available regarding direct comparisons of these agents, the optimal duration of therapy, or whether combinations of biologics are superior to individual treatments.<sup>11</sup>

Bronchial thermoplasty, a procedure approved in 2010 for severe asthma, delivers radiofrequency energy to the airway. The mechanisms by which this procedure affects the pathogenesis of asthma remain unclear; changes in adaptive immunity and airway smooth muscle have been suggested but not proven.<sup>73</sup> Reduced exacerbations (50%) and emergency department visits (85%) are seen for at least 1 year after treatment.<sup>74</sup> Trials of up to 5 years were not rigorously controlled, so evidence for long-term benefit is limited.<sup>30</sup> The GINA,<sup>13</sup> but not the NAEPP,<sup>12</sup> specify a role for bronchial thermoplasty. The American Thoracic Society and European Respiratory Society have recommended that bronchial thermoplasty be conducted within the context of a clinical trial or registry.<sup>75</sup>

### Prognosis

Asthma continues to be an important cause of morbidity and some mortality in the United States (Table 1). Rates of asthma mortality are particularly elevated among non-Hispanic African American patients (25.4 per million per year) compared with white patients (8.8 per million per year).<sup>2</sup>

Controller agents appear not to modify the natural history of asthma.<sup>12,13</sup> Patients with persistent disease should be counseled

that treatment for an extended period will likely be necessary. In patients with mild-moderate asthma whose disease is controlled with a daily regimen of low-medium dose of inhaled corticosteroids, the administration of these agents only at the time that short-acting  $\beta_2$ -agonists are used for relief of symptoms provides control not different from that achieved with daily inhaled corticosteroids, using a reduced dose of inhaled corticosteroids; however, this approach has not yet been incorporated into formal guidelines.<sup>76</sup>

Accelerated loss of lung function is seen in some, but not all, patients with asthma.<sup>77</sup> Loss of lung function is principally observed in patients in whom exacerbations are frequent (2% predicted greater annual loss of FEV<sub>1</sub> in patients with exacerbation compared with those without),<sup>78</sup> highlighting the potential importance of preventing exacerbations. However, no long-term controlled trials having trajectory of lung function as the primary outcome have been published, so the effects of guideline-based treatment on loss of lung function remain unclear.

## Conclusions

Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, availability of short-acting  $\beta_2$ -agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.

### ARTICLE INFORMATION

**Accepted Date:** June 6, 2017.

**Correction:** This article was corrected online on October 24, 2017, for incorrect dosage information in a table.

**Author Contributions:** Drs McCracken and Calhoun had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs McCracken and Veeranki contributed equally to this work. *Concept and design:* All authors.

*Acquisition, analysis, or interpretation of data:* McCracken, Calhoun.

*Drafting of the manuscript:* All authors.

*Critical revision of the manuscript for important intellectual content:* All authors.

*Statistical analysis:* Ameredes, Calhoun.

*Administrative, technical, or material support:* All authors.

*Supervision:* McCracken, Ameredes, Calhoun.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Calhoun reported receiving grant funding from AstraZeneca and the National Institutes of Health; receiving personal fees from Genentech; and grant funding from GlaxoSmithKline and MedImmune to

the University of Texas Medical Branch. No other disclosures were reported.

**Funding/Support:** This work was supported in part by Clinical and Translational Science Award funding from the National Center for Advancing Translational Sciences (UL1TR001439).

**Role of the Funder/Sponsor:** The National Center for Advancing Translational Sciences had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** We gratefully acknowledge the invaluable assistance of Anne Howard (Moody Medical Library, University of Texas Medical Branch). Ms Howard received no additional compensation for her contributions.

**Submissions:** We encourage authors to submit papers for consideration as a Review. Please contact Edward Livingston, MD, at [Edward.livingston@jamanetwork.org](mailto:Edward.livingston@jamanetwork.org) or Mary McGrae McDermott, MD, at [mdm608@northwestern.edu](mailto:mdm608@northwestern.edu).

### REFERENCES

- Centers for Disease Control and Prevention (CDC). Current asthma prevalence percent by age, United States: National Health Interview Survey, 2014. CDC website. <https://www.cdc.gov/asthma/nhis/2014/table4-1.htm>. Accessed November 30, 2016.
- Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. About underlying cause of death, 1999-2014. CDC website. <https://wonder.cdc.gov/ucd-icd10.html>. 2015. Accessed November 30, 2016.
- Centers for Disease Control and Prevention (CDC). Rate of discharges from short-stay hospitals, by age and first-listed diagnosis: United States, 2010: National Hospital Discharge Survey. CDC website. [https://www.cdc.gov/nchs/data/nhds/3firstlisted/2010first3\\_rateage.pdf](https://www.cdc.gov/nchs/data/nhds/3firstlisted/2010first3_rateage.pdf). Accessed November 30, 2016.
- Centers for Disease Control and Prevention (CDC). Twenty leading primary diagnosis and presence of chronic conditions at emergency department visits: United States, 2011: National Hospital Ambulatory Medical Care Survey. CDC website. [https://www.cdc.gov/nchs/data/ahcd/nhamcs\\_emergency/2011\\_ed\\_web\\_tables.pdf](https://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2011_ed_web_tables.pdf). Accessed November 30, 2016.

5. Centers for Disease Control and Prevention (CDC). Twenty leading primary diagnosis groups for office visits: United States, 2012: National Ambulatory Medical Care Survey. CDC website. [https://www.cdc.gov/nchs/data/ahcd/namcs\\_summary/2012\\_namcs\\_web\\_tables.pdf](https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2012_namcs_web_tables.pdf). Accessed November 30, 2016.
6. Centers for Disease Control and Prevention (CDC). Twenty leading primary diagnosis groups for outpatient department visits: United States, 2010. National Hospital Ambulatory Medical Care Survey. CDC website. [https://www.cdc.gov/nchs/data/ahcd/nhamcs\\_outpatient/2010\\_opd\\_web\\_tables.pdf](https://www.cdc.gov/nchs/data/ahcd/nhamcs_outpatient/2010_opd_web_tables.pdf). Accessed November 30, 2016.
7. Adams NP, Bestall JC, Lasserson TJ, Jones PW, Cates C. Fluticasone vs placebo for chronic asthma in adults and children. *Cochrane Database Syst Rev*. 2005;(4):CD003135.
8. Szeffler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. *Lancet*. 2008;372(9643):1065-1072.
9. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. *Am J Physiol Lung Cell Mol Physiol*. 2015;308(2):L130-L140.
10. Lazarus SC, Chinchilli VM, Rollings VJ, et al; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids and leukotriene receptor antagonist in asthma. *Am J Respir Crit Care Med*. 2007;175(8):783-790.
11. McCracken JL, Trippl JW, Calhoun WJ. Biologic therapy in the management of asthma. *Curr Opin Allergy Clin Immunol*. 2016;16(4):375-382.
12. National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute (NHLBI). Expert panel report 3: guidelines for the diagnosis and management of asthma. NHLBI website. <https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf>. Accessed November 30, 2016.
13. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2016. GINA website. <http://ginasthma.org>. Accessed November 30, 2016.
14. Tantisira KG, Lasky-Su J, Harada M, et al. Genome-wide association between *GLCCI1* and response to glucocorticoid therapy in asthma. *N Engl J Med*. 2011;365(13):1173-1183.
15. Liu Y, Wang ZH, Zhen W, et al. Association between genetic polymorphisms in the *ADAM33* gene and asthma risk: a meta-analysis. *DNA Cell Biol*. 2014;33(11):793-801.
16. Nicodemus-Johnson J, Laxman B, Stern RK, et al. Maternal asthma and microRNA regulation of soluble HLA-G in the airway. *J Allergy Clin Immunol*. 2013;131(6):1496-1503.
17. Moore WC, Bleecker ER, Curran-Everett D, et al; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *J Allergy Clin Immunol*. 2007;119:405-413.
18. Chervinsky P, van As A, Bronsky EA, et al; Fluticasone Propionate Asthma Study Group. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. *J Allergy Clin Immunol*. 1994;94(4):676-683.
19. Johansson SA, Dahl R. A double-blind dose-response study of budesonide by inhalation in patients with bronchial asthma. *Allergy*. 1988;43(3):173-178.
20. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB; Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. *Arch Intern Med*. 1998;158(11):1213-1220.
21. Israel E, Cohn J, Dubé L, Drazen JM; Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. *JAMA*. 1996;275(12):931-936.
22. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maeser FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. *Eur Respir J*. 1996;9(8):1684-1688.
23. Peters SP, Kunselman SJ, Icitovic N, et al; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. *N Engl J Med*. 2010;363(18):1715-1726.
24. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the Diskus device for the treatment of asthma. *Am J Respir Crit Care Med*. 2000;161(2, pt 1):527-534.
25. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol*. 2001;108(2):184-190.
26. Bel EH, Wenzel SE, Thompson PJ, et al; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2014;371(13):1189-1197.
27. Ortega HG, Liu MC, Pavord ID, et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*. 2014;371(13):1198-1207.
28. Castro M, Mathur S, Hargreave F, et al; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. *Am J Respir Crit Care Med*. 2011;184(10):1125-1132.
29. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med*. 2015;3(5):355-366.
30. Wechsler ME, Lavoie M, Rubin AS, et al; Asthma Intervention Research 2 Trial Study Group. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. *J Allergy Clin Immunol*. 2013;132(6):1295-1302.
31. Eaton T, Garrett J, Milne D, Frankel A, Wells AU. Allergic bronchopulmonary aspergillosis in the asthma clinic: a prospective evaluation of CT in the diagnostic algorithm. *Chest*. 2000;118(1):66-72.
32. Mims JW. Asthma: definitions and pathophysiology. *Int Forum Allergy Rhinol*. 2015;5(suppl 1):S2-S6.
33. Roux E, Molimard M, Savineau JP, Marthan R. Muscarinic stimulation of airway smooth muscle cells. *Gen Pharmacol*. 1998;31(3):349-356.
34. Hansbro PM, Starkey MR, Mattes J, Horvat JC. Pulmonary immunity during respiratory infections in early life and the development of severe asthma. *Ann Am Thorac Soc*. 2014;11(suppl 5):S297-S302.
35. Marketos SG, Ballas CN. Bronchial asthma in the medical literature of Greek antiquity. *J Asthma*. 1982;19(4):263-269.
36. Sokol K, Sur S, Ameredes BT. Inhaled environmental allergens and toxicants as determinants of the asthma phenotype. *Adv Exp Med Biol*. 2014;795:43-73.
37. White CW, Martin JG. Chlorine gas inhalation: human clinical evidence of toxicity and experience in animal models. *Proc Am Thorac Soc*. 2010;7(4):257-263.
38. Reno AL, Brooks EG, Ameredes BT. Mechanisms of heightened airway sensitivity and responses to inhaled SO<sub>2</sub> in asthmatics. *Environ Health Insights*. 2015;9(suppl 1):13-25.
39. Papadopoulos NG, Xepapadaki P, Mallia P, et al. Mechanisms of virus-induced asthma exacerbations: state-of-the-art: a GA2LEN and InterAirways document. *Allergy*. 2007;62(5):457-470.
40. Amaral AF, Ramasamy A, Castro-Giner F, et al. Interaction between gas cooking and *GSTM1* null genotype in bronchial responsiveness: results from the European Community Respiratory Health Survey. *Thorax*. 2014;69(6):558-564.
41. Ameredes BT. Beta-2-receptor regulation of immunomodulatory proteins in airway smooth muscle. *Front Biosci (Schol Ed)*. 2011;3:643-654.
42. Apter AJ, Reisine ST, Willard A, et al. The effect of inhaled albuterol in moderate to severe asthma. *J Allergy Clin Immunol*. 1996;98(2):295-301.
43. Goyal M, Jaseja H, Verma N. Increased parasympathetic tone as the underlying cause of asthma: a hypothesis. *Med Hypotheses*. 2010;74(4):661-664.
44. Kerstjens HA, O'Byrne PM. Tiotropium for the treatment of asthma: a drug safety evaluation. *Expert Opin Drug Saf*. 2016;15(8):1115-1124.
45. Cockcroft DW. Bronchial inhalation tests, I: measurement of nonallergic bronchial responsiveness. *Ann Allergy*. 1985;55(4):527-534.
46. Busse WW. Inflammation in asthma: the cornerstone of the disease and target of therapy. *J Allergy Clin Immunol*. 1998;102(4, pt 2):S17-S22.
47. Lane SJ, Lee TH. Mast cell effector mechanisms. *J Allergy Clin Immunol*. 1996;98(5, pt 2):S67-S71.
48. Robinson DS, Bentley AM, Hartnell A, Kay AB, Durham SR. Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. *Thorax*. 1993;48(1):26-32.
49. James AL, Elliot JG, Jones RL, et al. Airway smooth muscle hypertrophy and hyperplasia in asthma. *Am J Respir Crit Care Med*. 2012;185(10):1058-1064.

50. Rubin BK. Secretion properties, clearance, and therapy in airway disease. *Transl Respir Med.* 2014; 2:6.
51. Grigoraş A, Grigoraş CC, Giuscă SE, Căruntu ID, Amălinei C. Remodeling of basement membrane in patients with asthma. *Rom J Morphol Embryol.* 2016;57(1):115-119.
52. Huang SK, Xiao HQ, Kleine-Tebbe J, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. *J Immunol.* 1995;155(5): 2688-2694.
53. Gauvreau GM, El-Gammal AI, O'Byrne PM. Allergen-induced airway responses. *Eur Respir J.* 2015;46(3):819-831.
54. Liu T, Wu J, Zhao J, et al. Type 2 innate lymphoid cells: a novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. *Respir Med.* 2015;109(11):1391-1396.
55. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. *Nat Med.* 2013;19(8):977-979.
56. Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. *Curr Mol Med.* 2008;8(5):437-445.
57. Barnig C, Levy BD. Lipoxin A4: a new direction in asthma therapy? *Expert Rev Clin Immunol.* 2013;9(6):491-493.
58. Nakajima H, Hirose K. Role of IL-23 and Th17 cells in airway inflammation in asthma. *Immune Netw.* 2010;10(1):1-4.
59. Hosoki K, Itazawa T, Boldogh I, Sur S. Neutrophil recruitment by allergens contribute to allergic sensitization and allergic inflammation. *Curr Opin Allergy Clin Immunol.* 2016;16(1):45-50.
60. Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? *J Allergy Clin Immunol.* 2016;138(4):977-983.
61. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing—1999. *Am J Respir Crit Care Med.* 2000;161(1):309-329.
62. Leuppi JD. Bronchoprovocation tests in asthma: direct versus indirect challenges. *Curr Opin Pulm Med.* 2014;20(1):31-36.
63. Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS; A305 Study Group. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. *Respir Res.* 2009; 10(10):4.
64. Komarow HD, Myles IA, Uzzaman A, Metcalfe DD. Impulse oscillometry in the evaluation of diseases of the airways in children. *Ann Allergy Asthma Immunol.* 2011;106(3):191-199.
65. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. *Eur Respir J.* 1999;14(4):902-907.
66. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol.* 2004;113(1):59-65.
67. Dweik RA, Boggs PB, Erzurum SC, et al; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med.* 2011;184(5):602-615.
68. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. *N Engl J Med.* 2011;364(18):1695-1707.
69. Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. *N Engl J Med.* 2016;375(9):850-860.
70. Humbert M, Busse W, Hanaani NA, et al. Omalizumab in asthma: an update on recent developments. *J Allergy Clin Immunol Pract.* 2014;2(5):525-536.
71. Freitas PD, Ferreira PG, Silva AG, et al. The role of exercise in a weight-loss program on clinical control in obese adults with asthma: a randomized controlled trial. *Am J Respir Crit Care Med.* 2017;195(1):32-42.
72. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest.* 2006;129(1):15-26.
73. Laxmanan B, Hogarth DK. Bronchial thermoplasty in asthma: current perspectives. *J Asthma Allergy.* 2015;8:39-49.
74. Castro M, Rubin AS, Laviolette M, et al; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. *Am J Respir Crit Care Med.* 2010;181(2):116-124.
75. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [published correction appears in *Eur Resp J.* 2014;43(4):1216]. *Eur Respir J.* 2014;43(2):343-373.
76. Calhoun WJ, Ameredes BT, King TS, et al; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. *JAMA.* 2012;308(10): 987-997.
77. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators Group. Severe exacerbations and decline in lung function in asthma. *Am J Respir Crit Care Med.* 2009;179(1): 19-24.
78. Calhoun WJ, Haselkorn T, Miller DP, Omachi TA. Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma. *J Allergy Clin Immunol.* 2015;136(4):1125-1127.